Article

Subgroup analysis suggests TTT benefit in eyes presenting with poor vision

A subgroup analysis from the Transpupillary Thermotherapy of Occult Subfoveal Choroidal Neovascular Membranes in patients with Age-Related Macular Degeneration (TTT4CNV) study shows an increasingly beneficial effect of TTT over time in eyes with BCVA of 20/100 or worse, said Elias Reichel, MD.

May 4

- Fort Lauderdale, FL - A subgroup analysis from the Transpupillary Thermotherapy of Occult Subfoveal Choroidal Neovascular Membranes in patients with Age-Related Macular Degeneration (TTT4CNV) study shows an increasingly beneficial effect of TTT over time in eyes with BCVA of 20/100 or worse, said Elias Reichel, MD.

Patients eligible for the TTT4CNV trial had subfoveal occult CNV with a maximum diameter of 3 mm and visual acuity of 20/50 to 20/400. They were randomized 2:1 to TTT (800 mW for 60 seconds with a 3-mm spot size) or sham treatment. One retreatment only was allowed after 3 months, according to the investigatorís discretion.

Previously reported intent-to-treat analysis results for the entire enrolled cohort of 305 patients found no statistically significant difference between TTT and sham study groups for the primary efficacy endpoint (avoidance of moderate vision loss). However, based in part on the observation of trends favoring treatment, various subgroup analyses were undertaken. Results from other CNV treatment studies and case series of TTT provided further rationale for studying the subgroup with baseline visual acuity of 20/100 or worse.

The subgroup analyses showed eyes treated with TTT had significantly less mean visual acuity loss and a significantly higher proportion had improved visual acuity. Trends favoring treatment were noted in analyses of avoidance of moderate and severe vision loss. From a safety perspective, there was no difference between groups in rates of severe vision loss at 1 month post-treatment.

"These subgroup analyses indicate that TTT is beneficial compared to natural history in eyes with subfoveal occult CNV and BCVA of 20/100 or worse in patients who also meet the other key eligibility criteria of this clinical trial," Dr. Reichel said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.